US Stock Insider Trading | Option Care disclosed 13 insider transactions on February 24

2026-03-07 01:26:57

Abstract generation in progress

On February 24, 2026, Option Care (OPCH) disclosed 13 insider transactions. Director Rademacher John Charles sold 138,400 shares on February 22, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 24, 2026	Executive	Smyser Collin	February 22, 2026	Sell	17,400	35.69	622,600
February 24, 2026	Executive	Maggio Nicole	February 22, 2026	Sell	991	35.69	35,400
February 24, 2026	Executive	Whitworth Luke	February 22, 2026	Sell	28,000	35.69	1,000,900
February 24, 2026	Director	Rademacher John Charles	February 22, 2026	Sell	148,400	35.69	5,297,900
February 24, 2026	Executive	Bavaro Michael	February 22, 2026	Sell	13,400	35.69	478,200
February 24, 2026	Executive	Grashoff Christopher L.	February 22, 2026	Sell	2,486	35.69	88,700
February 19, 2026	Executive	Grashoff Christopher L.	February 17, 2026	Sell	259	35.24	9,127.16
February 19, 2026	Executive	Maggio Nicole	February 17, 2026	Sell	247	35.24	8,704.28
February 19, 2026	Executive	Bavaro Michael	February 17, 2026	Sell	551	35.24	19,400
February 19, 2026	Executive	Whitworth Luke	February 17, 2026	Sell	508	35.24	17,900

【Company Profile】

Option Care Health, Inc. is the largest independent provider of home and alternate-site infusion services. With nearly 40 years of clinical care experience, the company offers patient-centered, cost-effective infusion therapy. Infusion services include clinical management, nursing support, and care coordination. The company has a multidisciplinary team of approximately 2,900 clinicians, including pharmacists, nurses, and nutritionists, capable of providing infusion services to nearly all patients across the U.S. who require treatment for complex and chronic diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes